{"cik":1540171,"taxonomy":"us-gaap","tag":"OperatingLeaseRightOfUseAsset","label":"Operating Lease, Right-of-Use Asset","description":"Amount of lessee's right to use underlying asset under operating lease.","entityName":"Avalyn Pharma Inc.","units":{"USD":[{"end":"2025-12-31","val":1530000,"accn":"0001193125-26-254623","fy":2026,"fp":"Q1","form":"10-Q","filed":"2026-06-03"},{"end":"2025-12-31","val":1530000,"accn":"0001193125-26-345820","fy":2026,"fp":"Q2","form":"10-Q","filed":"2026-08-12"},{"end":"2025-12-31","val":1530000,"accn":"0001193125-26-457071","fy":2026,"fp":"Q3","form":"10-Q","filed":"2026-11-12","frame":"CY2025Q4I"},{"end":"2026-03-31","val":1421000,"accn":"0001193125-26-254623","fy":2026,"fp":"Q1","form":"10-Q","filed":"2026-06-03","frame":"CY2026Q1I"},{"end":"2026-06-30","val":2140000,"accn":"0001193125-26-345820","fy":2026,"fp":"Q2","form":"10-Q","filed":"2026-08-12","frame":"CY2026Q2I"},{"end":"2026-09-30","val":1953000,"accn":"0001193125-26-457071","fy":2026,"fp":"Q3","form":"10-Q","filed":"2026-11-12","frame":"CY2026Q3I"}]}}